the main point is that Ascelia is on track for a re-evaluation on SPARKLE in May 2024 and the cash r...
Rapportkommentar OncoZenge släppte under förra veckan sin rapport för det tredje kvartalet.
Lägre försäljning än förväntat – upprepad guidning för 2023 Calliditas Q3-rapport kom in under både ...
Fortsatt svaga försäljningssiffror Omsättningen uppgick till 13,3 mkr (18,5) och rörelseresultatet u...
Intellego Technologies redovisade ökad nettoomsättning och EBIT i det tredje kvartalet.
Redeye comments on Nitro Games’ new development agreement with Netflix
DevPort rapporterar ett stabilt Q3 med tillväxt i såväl försäljning som resultat och kassaflöde.
Sales -20.6%, adj. EBIT -2.6% vs. ABGSCe, improved cost control Expects increasing demand for eMELT ...
Redeye comments on FlexQube’s Q3 report, which was weaker than expected both in terms of sales and p...
Sales 40.3m (-7% vs. ABGSCe), adj. EBIT 16.7m (ABGSCe 19.
Redeye notes that Egetis’ Q3 report presented SEK12.
Redeye comments on Fantasma Games’ Q3 results, which came in softer than expected.
Redeye comments on G5’s Q3-results where revenue came in slightly below expectations while EBIT was ...
Redeye provides an update on Gasporox after its Q3 2023 report.
Redeye comments on the rights issue announced by Medivir yesterday evening.
Redeye provides an update on BeammWave following its Q3 2023 report.
Redeye saw sales that were in line with our expectations.
Q3 EBITDA of USD 16.4m, in line with ABGSCe But soft production lowers estimates Fair value range re...
Cibus' Q3 2023 income from property management (IFPM) was 16% ahead of Infront consensus, adjusted f...
Redeye retains its positive stance towards Hanza following a solid Q3 report, with the strong margin...
